[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6T61ZcHDD5NjPbHARGRzCE_01k_vs98Wq9upkUP7Rb8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"Hasselt University",[4],203,false,28,3,51305,0,197,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Multiple Sclerosis",32,{"name":18,"count":19},"Low Back Pain",9,{"name":21,"count":22},"Heart Failure",8,{"name":24,"count":25},"Stroke",7,{"name":27,"count":28},"Coronary Artery Disease",6,{"name":30,"count":28},"Lung Cancer",{"name":32,"count":33},"Breast Cancer",5,{"name":35,"count":33},"Obesity",[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,72,99,117,135,161,179,206,224,251],{"intervention":46,"totalTrials":47,"cells":48},"Ferric Carboxymaltose",1,{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":70},{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[],{"trials":58,"activeCount":11},[59],{"nctId":60,"briefTitle":61,"status":62,"phases":63,"primaryCompletion":64,"completion":65,"start":66,"enrollment":67,"conditions":68,"interventions":69},"NCT03380520","Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy","COMPLETED",[42],"2020-12-31","2021-08-04","2017-10-01",75,[21],[46],{"trials":71,"activeCount":11},[],{"intervention":73,"totalTrials":47,"cells":74},"Combination therapy with acetazolamide and low-dose loop diuretics",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":97},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":86,"briefTitle":87,"status":62,"phases":88,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":94},"NCT01973335","Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure",[42],"2017-04","2017-10","2013-11",34,[21],[73,95,96],"High-dose loop diuretics","Upfront therapy with oral spironolactone",{"trials":98,"activeCount":11},[],{"intervention":95,"totalTrials":47,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":115},{"trials":102,"activeCount":11},[],{"trials":104,"activeCount":11},[],{"trials":106,"activeCount":11},[],{"trials":108,"activeCount":11},[],{"trials":110,"activeCount":11},[111],{"nctId":86,"briefTitle":87,"status":62,"phases":112,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":113,"interventions":114},[42],[21],[73,95,96],{"trials":116,"activeCount":11},[],{"intervention":96,"totalTrials":47,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":133},{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[],{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[],{"trials":128,"activeCount":11},[129],{"nctId":86,"briefTitle":87,"status":62,"phases":130,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":131,"interventions":132},[42],[21],[73,95,96],{"trials":134,"activeCount":11},[],{"intervention":136,"totalTrials":47,"cells":137},"beta blockers",{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":159},{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[],{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[],{"trials":147,"activeCount":11},[148],{"nctId":149,"briefTitle":150,"status":62,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT02200822","Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients",[42],"2019-02","2014-07",80,[156],"Heart Failure (HF)",[136,158],"RAAS blockers",{"trials":160,"activeCount":11},[],{"intervention":158,"totalTrials":47,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":177},{"trials":164,"activeCount":11},[],{"trials":166,"activeCount":11},[],{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[173],{"nctId":149,"briefTitle":150,"status":62,"phases":174,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":175,"interventions":176},[42],[156],[136,158],{"trials":178,"activeCount":11},[],{"intervention":180,"totalTrials":47,"cells":181},"Oxaliplatin: BSA-based HIPEC",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":202,"NA":204},{"trials":183,"activeCount":11},[],{"trials":185,"activeCount":11},[],{"trials":187,"activeCount":11},[],{"trials":189,"activeCount":11},[190],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT03028155","Concentration- Versus Body Surface Area-based HIPEC in Colorectal Peritoneal Carcinomatosis' Treatment","UNKNOWN",[41],"2018-08","2016-11",60,[199],"Colorectal Peritoneal Carcinomatosis",[180,201],"Oxaliplatin: Concentration-based HIPEC",{"trials":203,"activeCount":11},[],{"trials":205,"activeCount":11},[],{"intervention":201,"totalTrials":47,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":220,"NA":222},{"trials":209,"activeCount":11},[],{"trials":211,"activeCount":11},[],{"trials":213,"activeCount":11},[],{"trials":215,"activeCount":11},[216],{"nctId":191,"briefTitle":192,"status":193,"phases":217,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":218,"interventions":219},[41],[199],[180,201],{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[],{"intervention":225,"totalTrials":47,"cells":226},"Daily medical treatment",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":228,"activeCount":11},[],{"trials":230,"activeCount":11},[],{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"trials":236,"activeCount":11},[],{"trials":238,"activeCount":11},[239],{"nctId":240,"briefTitle":241,"status":242,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":250},"NCT05480566","Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD","TERMINATED",[43],"2023-12-01","2022-06-01",35,[248,249],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Acute Exacerbation of COPD",[225],{"intervention":252,"totalTrials":47,"cells":253},"Loop diuretic downtitration",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":255,"activeCount":11},[],{"trials":257,"activeCount":11},[],{"trials":259,"activeCount":11},[],{"trials":261,"activeCount":11},[],{"trials":263,"activeCount":11},[],{"trials":265,"activeCount":11},[266],{"nctId":267,"briefTitle":268,"status":242,"phases":269,"primaryCompletion":270,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":275},"NCT02288819","Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure",[43],"2016-03","2016-04","2014-09",50,[21],[252]]